Title

SOF/VEL/VOX for 12 weeks in NS5A-inhibitor experienced HCV-infected patients: Results of the deferred treatment group in the phase 3 POLARIS-1 study.

Document Type

Conference Proceeding

Publication Date

2017

Publication Title

Hepatology (Baltimore, Md.)

Volume

66

First Page

633A

Last Page

634A

Share

COinS